Diabetes Journal Publications
This page includes links to Lilly sponsored clinical trials that have been published in peer reviewed journals over the last 3 years. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.
If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please Contact Lilly services below for further assistance.
Basaglar
LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels
Published Date: September 21, 2017No Publications.
Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self-titrating insulin glargine U-100
Published Date: August 2, 2019Lilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study
Published Date: May 22, 2019Lilly Insulin Glargine Versus Lantus® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)
Published Date: January 2, 2019Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2
Published Date: July 23, 2018Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus® Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation
Published Date: May 31, 2018Characteristics of insulin-Naïve people with type 2 diabetes who successfully respond to insulin glargine U100 after 24 weeks of treatment: a meta-analysis of individual participant data from 3 randomized clinical trials
Published Date: May 8, 2018Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study
Published Date: March 14, 2018Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine
Published Date: March 30, 2017Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study
Published Date: April 23, 2020Glucagon
No Publications.
No Publications.
NASAL GLUCAGON DELIVERY IS MORE SUCCESSFUL THAN INJECTABLE DELIVERY: A SIMULATED SEVERE HYPOGLYCEMIA RESCUE
Published Date: April 15, 2020Nasal glucagon as a viable alternative for treating insulin-induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: A phase 3 randomized crossover study
Published Date: March 1, 2020A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting
Published Date: March 22, 2018Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting
Published Date: March 22, 2018Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial
Published Date: November 19, 2017Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study
Published Date: May 30, 2017Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
Published Date: February 16, 2016Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
Published Date: December 17, 2015No Publications.
Humalog
Humalog® U-100 | Full Prescribing Information
Humalog® U-200 | Full Prescribing Information
Humalog® MIX50/50™ | Full Prescribing Information
Humalog® MIX75/25™ | Full Prescribing Information
No Publications.
No Publications.
No Publications.
Insulin exposure mitigates the increase of arterial stiffness in patients with type 2 diabetes and albuminuria: an exploratory analysis
Published Date: May 17, 2019Fasting experience of patients with Type 2 diabetes mellitus on insulin therapy during Ramadan: VISION Ramadan substudy
Published Date: February 27, 2019Patterns and trends in insulin initiation and intensification among patients with Type 2 diabetes mellitus in the Middle East and North Africa region
Published Date: January 14, 2019Relative Contribution of Fasting and Postprandial Blood Glucose in Overall Glycemic Control: Post Hoc Analysis of a Phase IV Randomized Trial
Published Date: March 24, 2018When basal insulin is not enough: successful strategies for insulin intensification in patients with type 2 diabetes mellitus
Published Date: December 15, 2017CREED study: Hypoglycaemia during Ramadan in individuals with Type 2 diabetes mellitus from three continents
Published Date: July 13, 2017Simulation-Based Evaluation of Dose-Titration Algorithms for Rapid-Acting Insulin in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antihyperglycemic Medications
Published Date: July 3, 2017Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial
Published Date: May 24, 2017Humulin
Humulin® R (U-100) | Full Prescribing Information
Humulin® R (U-500) | Full Prescribing Information
Humulin® 70/30 | Full Prescribing Information
Humulin® N U-100 | Full Prescribing Information
No Publications.
No Publications.
Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study.
Published Date: December 22, 2019No Publications.
Lyumjev
Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects
Published Date: June 13, 2020Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study
Published Date: May 29, 2020Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial
Published Date: May 29, 2020Ultra Rapid Lispro Lowers Postprandial Glucose and More Closely Matches Normal Physiological Glucose Response Compared to Other Rapid Insulin Analogs: A Phase 1 Randomized, Crossover Study
Published Date: May 21, 2020Ultra-Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog® in Japanese patients with type 1 diabetes
Published Date: December 9, 2019Ultra Rapid Lispro Demonstrates Similar Time in Target Range to Lispro With a Hybrid Closed-Loop System
Published Date: November 25, 2021Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2
Published Date: 09 March 2021Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study
Published Date: December 31, 2020Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D
Published Date:** Online: 2 July 2020, Print: 20 November 2020Ultra Rapid Lispro Improves Postprandial Glucose Control Compared With Lispro in Patients With Type 1 Diabetes: Results from the 26-Week PRONTO-T1D Study
Published Date: June 15, 2020Ultra Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Sub-Study
Published Date: May 21, 2020No Publications.
Mounjaro
Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
Published Date: June 08, 2022Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
Published Date: April 22, 2022Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
Published Date: March 29, 2021Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
Published Date: February 24, 2022Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Published Date: January 27, 2020Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Published Date: November 17, 2018Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Published Date: April 22, 2022Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Published Date: April 22, 2022Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Published Date: November 13, 2021Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Published Date: August 14, 2021Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Published Date: August 5, 2021Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Published Date: July 10, 2021Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Published Date: February 8, 2021No Publications.
Trulicity
No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide
Published Date: March 29, 2017Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion
Published Date: February 17, 2017Change in HbA1c Across the Baseline HbA1c Range in Type 2 DiabetesPatients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
Published Date: May 4, 2019Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme
Published Date: March 30, 2018Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c
Published Date: August 17, 2017No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer
Published Date: July 29, 2017Assessment of PancreasSafety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide
Published Date: March 10, 2017Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
Published Date: April 10, 2020Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c
Published Date: April 3, 2020Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1
Published Date: March 26, 2020Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis
Published Date: November 23, 2019Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial
Published Date: July 31, 2019Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Published Date: July 13, 2019Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2)
Published Date: June 21, 2019Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post-hoc analyses of a randomized, double-blind, phase III study
Published Date: May 18, 2019Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
Published Date: May 4, 2019Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups
Published Date: March 15, 2019Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)
Published Date: February 14, 2019Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States
Published Date: February 3, 2019Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial
Published Date: August 21, 2018Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Published Date: June 14, 2018Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme
Published Date: March 30, 2018Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration
Published Date: March 23, 2018Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
Published Date: February 23, 2018Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes
Published Date: December 20, 2017Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes
Published Date: September 14, 2017Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c
Published Date: August 17, 2017No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer
Published Date: July 29, 2017Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies
Published Date: June 12, 2017Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND ) trial on the cardiovascular effects of dulaglutide
Published Date: June 1, 2017Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD -9)
Published Date: April 10, 2017Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan
Published Date: March 29, 2017Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide
Published Date: March 10, 2017Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment
Published Date: March 7, 2017Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
Published Date: May 4, 2019Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme
Published Date: March 30, 2018Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration
Published Date: March 23, 2018Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c
Published Date: August 17, 2017Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD -9)
Published Date: April 10, 2017